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45.2%), or antidepressants. However, younger children were more likely than older 
children to receive antipsychotics (65.7% versus 53.1%) and stimulants (45.0% versus 
29.9%). Between 2005 and 2007, psychotropic medication use changed within 
the younger age group, with anticonvulsant use decreasing by nearly 10% and 
stimulant use increasing by 7%. CONCLUSIONS: Psychotropic medication use is 
prevalent in both younger and older children with bipolar spectrum disorders. 
Younger children are signiﬁcantly more likely to receive antipsychotics and stimulants 
as compared with older children, and less likely to receive lithium, anticonvulsants, 
or antidepressants.
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NATIONAL TRENDS IN PRESCRIBING ANTIDEPRESSANTS FOR 
DEPRESSION—BEFORE AND AFTER FDA ADVISORY ON RISK OF 
SUICIDALITY AMONG CHILDREN AND ADOLESCENTS
Chen SY1, Toh S2
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OBJECTIVES: To evaluate the national trends in prescribing antidepressants for 
depression before and after the FDA advisory regarding the risk of suicidality for 
pediatric patients in 2003. METHODS: Visit-based data 1996–2007 from the 
National Ambulatory Medical Care Survey and the National Hospital Ambulatory 
Medical Care Survey were analyzed. Data were analyzed among children aged 5–17 
years. For comparison, we also analyzed data from adults. We reported the number 
of visits (ofﬁce-based and outpatient combined) with a diagnosis of depression and 
number of visits and proportion with antidepressants prescribed for each two-year 
period. Robust 95% conﬁdence intervals (CI) were calculated and the results were 
weighted to reﬂect national estimates. RESULTS: Among children, the number of 
depression visits increased steadily during the pre-advisory period from 1996–1997 
(2.4 million; 95% CI: 1.8–3.1) to 2002–2003 (4.4 million; 3.3–5.5), and decreased 
by 16% in 2004–2005 (3.7 million; 2.8–4.5) and 27% in 2006–2007 (3.2. million; 
2.3–4.1) compared with the level in 2002–2003 following the advisory. The number 
of visits with any antidepressant prescribed increased two-fold from 1996–1997 (1.3 
million; 0.9–1.7) to 2002–2003 (2.9 millions; 2.3–3.6), and decreased by 28% in 
2006–2007 (2.1 millions; 1.5–2.6). The proportion of depression visits with any 
antidepressant prescribed increased from 1996–1997 (54%; 42%–67%) to 2002–
2003 (66%; 59%–74%), and remained stable in 2004–2005 (65%; 56%–74%) and 
2006–2007 (64%; 55%–72%) after the advisory. Among adults, the increase in trends 
was not interrupted by the advisory. Proportion of use for ﬂuoxetine continued to 
increase after the advisory, while the increasing trend reversed after the advisory for 
non-ﬂuoxetine SSRIs among children. CONCLUSIONS: There was a downward trend 
in ambulatory utilization of antidepressants prescribed for depression among children 
after the FDA advisory, coincided with a decrease in visits with a diagnosis of depres-
sion. There appeared to be a switch in utilization from non-ﬂuoxetine SSRIs to 
ﬂuoxetine.
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ASSOCIATION OF PATIENT CHARACTERISTICS WITH THE USE OF 
PHARMACOTHERAPY, PSYCHOTHERAPY AND COMBINED 
TREATMENT FOR DEPRESSION
Luthra R, Li C, Helm ME, Said Q
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To examine the association of patient characteristics including age, 
sex, race, geographic diversity, income status, insurance type, perceived mental health 
status, perceived health status, and co-morbidities of depression with the use of phar-
macotherapy, psychotherapy and combined treatment for depression. METHODS: 
Depressed individuals in the age group 18–65 were identiﬁed from the Medical 
Expenditure Panel Survey 1998–2006. Pregnant women and individuals with other 
mental health illnesses were excluded. Individuals with at least four antidepressant 
prescriptions yearly without any psychotherapy formed the pharmacotherapy group. 
Individuals with at least four psychotherapy visits yearly and no antidepressants 
formed the psychotherapy group. Combined therapy group included individuals with 
at least four psychotherapy visits and four antidepressants yearly. Survey weights were 
applied to get national estimates. RESULTS: There were estimated 1,115,091 patients 
in the combined group, 3,173,122 in the pharmacotherapy group and 733,264 in the 
psychotherapy group. Patients in the group 46–65 years were 88% (p = 0.000) more 
likely to get pharmacotherapy than combined therapy, and 45% (p = 0.007) less likely 
to get psychotherapy compared to patients in the age group 18–30. Patients not living 
in a Metropolitan Statistical Area (MSA) were 80% (p < 0.000) more likely to receive 
pharmacotherapy than combined therapy, compared to patients living in MSA. 
Patients other than white and black have 85% (p = 0.040) higher likelihood of receiv-
ing psychotherapy than the combined therapy compared with whites. Patients with 
self-reported fair or poor physical health were 70% (p = 0.002) less likely to receive 
psychotherapy than combined therapy, compared to those reporting excellent health. 
Self-reported poor mental health predicts higher likelihood of receiving combined 
therapy than pharmacotherapy or psychotherapy alone (p < 0.000). CONCLUSIONS: 
There are signiﬁcant differences among the three treatment groups based on their 
demographic characteristics. Age, region, perceived overall health status and perceived 
mental health status were signiﬁcant predictors of treatment received by the patients.
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TRENDS IN U.S. OUTPATIENT PHYSICIAN VISITS AND MEDICATION 
TREATMENT PATTERNS FOR PEDIATRIC ADHD: 1998–2007
Simeone JC, Quilliam BJ
University of Rhode Island, Kingston, RI, USA
OBJECTIVES: To describe 10-year trends in patient, physician and prescribed medica-
tions during outpatient visits for pediatric attention-deﬁcit/hyperactivity disorder 
(ADHD) METHODS: We identiﬁed all visits in children (3–18) with ADHD (ICD-9 
314.00/314.01) from 1998–2007 utilizing two national probability samples: the 
National Ambulatory Medical Care Survey and the National Hospital Ambulatory 
Medical Care Survey. We excluded pre/post surgery visits for a ﬁnal sample of 584,276 
visits and then weighted these visits to be representative of the US (using SUDAAN 
software) before calculating frequencies to characterize trends in patient and practice 
factors, as well as ADHD medication utilization. RESULTS: Visits for ADHD in 
children increased from 7.9 to 15.3 million (93%) from 1998–2007. Across all years, 
∼75% of visits were made by males. Visits were frequently made by white children 
(>80% in all years) with a trend of increasing visits by non-white children by 2006–
2007 (13.0% in 1998–1999 to 20.1% by 2006–2007). Visits among pediatricians rose 
from 38.3% in 1998–1999 to 48.4% in 2006–2007 with a decrease in specialist visits 
(from 43.1% to 33.7% of all visits). Across all years, mono-therapy was the predomi-
nant medication prescription (>60%), although ∼1/3rd of all visits did not note an 
ADHD medication. The use of methylphenidate mono-therapy dropped from 40.8% 
in 1998–1999 to 27.9% in 2006–2007. Dextroamphetamine mono-therapy rose from 
19.3% to 28.7% from 1998–1999 to 2002–2003, but then fell to 22.3% by 2006–
2007. The use of newer non-stimulant medications was apparent starting in 2002, but 
remained low (∼10%) across the rest of the interval. CONCLUSIONS: Visits made 
by children with ADHD increased over the decade, while use of medications for 
ADHD, particularly stimulants, decreased by 2006–2007 with no corresponding 
increase in the use of newer non-stimulant agents. New therapeutic options, changing 
guidelines, and emerging safety concerns make this an important area for ongoing 
research.
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WEB-SURVEYS: REAL WORLD EVIDENCE GATHERING AND 
MINIMIZING UNCERTAINTY IN ECONOMIC MODELS
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OBJECTIVES: From a Canadian societal perspective, little is known about the impact 
of Attention Deﬁcit Hyperactivity Disorder (ADHD) in adults. A methodology for the 
design and conduct of a web-based survey used to populate a Canadian economic 
model is described. METHODS: An IRB approved, wed-based survey was adminis-
tered to evaluate the impact of ADHD in pre-identiﬁed Canadian subjects with this 
condition. There were 3 subgroups of interest: an ADHD group with self-reported 
controlled symptoms, an ADHD group with self-reported uncontrolled symptoms, and 
a non-ADHD reference group. Eligible participants received a 28-item questionnaire 
(English or French) which evaluated socio-demographic characteristics, ADHD treat-
ment, co-morbidities, health care resource utilization, functional status (Sheehan Dis-
ability Scale), productivity (Work Productivity Assessment and Activity Impairment; 
WPAI), and health-related quality of life (EQ-5D). Validation rules were pre-pro-
grammed to optimize data quality and survey completion at the point of data entry. 
EQ-5D utilities and productivity losses from WPAI were used to inform an economic 
model. Other data were used as supportive information. RESULTS: The targeted 
number of completed questionnaires, n = 174, was reached within 2 weeks of study 
launch after 1,878 survey invitations were circulated. More speciﬁcally, 69 controlled, 
70 uncontrolled and 35 non-ADHD subjects responded. Among participants, 56% 
were male, mean age was 35 years, 43% were diagnosed with ADHD in adulthood, 
and the majority responded in English. Functional status and utility values were sig-
niﬁcantly lower for subjects with uncontrolled versus controlled ADHD. Employment 
rates were lower (59% vs. 74%, p = 0.06), and overall work impairment was signiﬁ-
cantly higher for uncontrolled versus controlled ADHD subjects, respectively. CON-
CLUSIONS: Web-based surveys are a cost and time efﬁcient methodology for evidence 
gathering in support of economic evaluations. Despite some inherent limitations of 
online studies, such as generalizability, survey variables and outcomes can be tailored 
to collect data from populations and sub-groups of interest.
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EXAMINATION OF DOCTORS’ PRACTICE AND PRESCRIBING 
PATTERNS TOWARD SELECTIVE SEROTONIN REUPTAKE INHIBITORS 
AND SERTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
Baser O1, Wang L2, Gust C2, Dysinger A2
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA
OBJECTIVES: None of the published literature comparing outcomes measures 
between serotonin reuptake inhibitors (SSRIs) and sertonin-norepinephrine reuptake 
inhibitors (SNRIs) control for doctors’ practice and prescribing patterns due to the 
limitations of claims databases. We showed how to derive doctors’ practice and 
prescribing patterns for this group of patients from U.S. claims data. METHODS: 
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Based on U.S. claims data, we assigned doctors IDs based on the physician who treated 
the enrollee for the longest period of time after eliminating any emergency room, labo-
ratory, and radiology services. Physician prescribing patterns were then calculated 
from prescription drug records. Patients were grouped as generic SSRIs, non-generic 
SSRIs, and SNRIs. RESULTS: We identiﬁed the doctors’ prescribing pattern with the 
percentage of time they prescribed SSRIs, non-generic SSRIs and SNRIs. We showed 
that patients were more likely to be prescribed generic SSRIs relative to non-generic 
SSRIs if doctors’ prescribing patterns favored generic prescription (p = 0.000). Simi-
larly, patients were less likely to be in the SSRIs group if doctors’ prescribing patterns 
favored SNRI prescription (p = 0.000). CONCLUSIONS: Doctors’ prescribing pat-
terns are important factors for decisions on treatment. Any outcomes models (compli-
ance, or treatment effect on health care utilization and cost) should control for these 
patterns.
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TIME SERIES ANALYSIS TO EXAMINE THE EFFECT OF GUIDELINES
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OBJECTIVES: Application of a segmented times series model to measure the effect of 
guidelines on outcomes measures. METHODS: To isolate the effect of guidelines, we 
need to control for three different factors: 1) Baseline differences between the two 
groups, 2) Step-wise differences at the intervention point, and 3) Trend differences 
after the intervention. The segmented times series model was combined with the 
propensity score matching technique. The segmented time series model contained two 
predictor variables: the binary intervention variable and an interval coding for time. 
The kitchen sink approach was used for propensity score matching and the segmented 
time series model controlled for the confounding inﬂuence of any underlying trend. 
The ﬁnal model ensured that any estimated change in the mean level of the series after 
intervention was not simply due to the series’ trend. RESULTS: Using U.S. claims data, 
we analyzed the effect of the American Psychiatric Association’s consensus statement 
on glucose monitoring for patients on atypical antipsychotic drugs. Glucose screening 
rose 1% per quarter among antipsychotic-treated patients before release of the guide-
lines, compared to 0.5% per quarter after (P = 0.005 for trend). Monitoring rates 
were 16.07% before release of the guidelines and 18.76% after (P < 0.001). CONCLU-
SIONS: The segmented time series model can provide a clear picture about both trend 
and intervention effect when analyzing the effects of guidelines.
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AGREEMENT BETWEEN PATIENTS WITH MILD DEMENTIA AND 
CAREGIVERS ON THE PROMIS CAT MEASURE OF PERCEIVED 
COGNITIVE FUNCTION
Nerenz DR, Pietrantoni L, Schultz L, Garden B, Shatz R
Henry Ford Hospital, Detroit, MI, USA
OBJECTIVES: The PROMIS measure of Perceived Cognitive Function has gone 
through multiple cycles of development and validation testing, but has not been 
extensively tested in clinical settings, particularly among patients being treated for 
neurological conditions and/or cognitive deﬁcits. We sought to do an initial examina-
tion of the extent to which patients being treated for mild dementia and their caregiv-
ers would agree in their assessment of patient cognitive function using the PROMIS 
PCF measure. METHODS: A total of 14 consecutive patients being seen in the Neurol-
ogy outpatient clinic at Henry Ford Hospital for a diagnosis of dementia, as well as 
one adult caregiver per patient, were invited to complete the PROMIS Perceived 
Cognitive Function CAT measure in reference to the patient’s current level of cognitive 
function. Several analyses of agreement between caregiver and patient reports were 
conducted. RESULTS: All patients and all caregivers were able to successfully com-
plete the PROMIS PCF measure. There was no signiﬁcant difference between patients 
and caregivers in either mean raw score, mean T-score, or standard error for the 
measure. The score ranges for caregivers and patients were quite comparable. The 
Pearson correlation coefﬁcients for association between patient and caregiver 
responses were .246 and .286 for raw score and t-score, respectively (both n.s.). 
CONCLUSIONS: The lack of signiﬁcant difference between patients and caregivers 
on mean response suggests possible validity of the PCF measure for group-level analy-
ses, but the relatively low correlations between patient and caregiver suggest caution 
about use of the measure at the individual patient level. The next step of analysis will 
involve comparison of patient PCF scores to scores on objective measures of cognitive 
function.
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ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID 
ARTHRITIS (RA)—FINDINGS FROM A RETROSPECTIVE CLAIMS 
DATABASE ANALYSIS USING A PRE-PROGRAMMED DATA ANALYSIS 
TOOL
Chiappinelli R1, McNeeley B1, Byrd J2, Ollinger E2
1HealthCore, Wilmington, DE, USA, 2Dymaxium Inc, Toronto, ON, Canada
OBJECTIVES: RA is a systemic disease resulting in comorbidities that affect quality 
of life, prognosis and outcomes. Comorbid illnesses can impact treatment, medical 
costs, disability and risk of mortality. Rheumatoid Arthritis Outcomes Analyzer, a 
validated claims data analysis tool with a user-friendly interface was used to character-
ize comorbidities in patients with RA. METHODS: The study included patients age 
18 or older with at least 2 diagnoses of RA (ICD-9 CM 714.0X) ≥ 2 months apart 
between January 2005 and December 2007 from the HealthCore Integrated Research 
DatabaseSM. Patients must have received ≥ one traditional (non-biologic) or biologic 
DMARD medication with RA diagnoses at least two months apart. All medical and 
pharmacy claims were entered into the ﬁnal dataset. RESULTS: A total of 25,856 RA 
patients entered into the analysis (mean age = 56; 74.8% female). The overall mean 
Charlson Comorbidity Index (CCI) was 2.00 (SD = 1.63) and was higher for males 
(mean = 2.18; SD = 1.85) than females (mean = 1.94; SD = 1.55). In the 18 to 44 age 
group, females tended to have a higher CCI (mean = 1.38; SD = 0.91) than males 
(mean = 1.30; SD = 0.81). This trend reverses in older patients where the mean CCI 
in males in the 45 to 64 and ≥ 65 age groups is 1.90 (SD = 1.50) and 3.31 (SD = 2.39) 
respectively versus 1.76 (SD = 1.29) and 2.80 (SD = 2.07) in females. The most fre-
quent comorbid conditions for all patients were; chronic pulmonary disease, diabetes, 
cerebrovascular disease, tumor, congestive heart failure, peripheral vascular disease 
and renal disease. CONCLUSIONS: This analysis explores and differentiates the CCI 
by gender and age group in patients with RA using a validated claims data analysis 
tool. Further study will examine the relationship between comorbidity and health-
related and cost outcomes.
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ESTIMATING HEALTH-RELATED UTILITY FROM CLINICALLY ASSESSED 
DISEASE SEVERITY IN ANKYLOSING SPONDYLITIS
Poole CD1, Singh A2, Freundlich B3, Koenig A3, Currie CJ4
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OBJECTIVES: We sought to conduct a statistical mapping analysis between a stan-
dard investigator assessment of disease severity in ankylosing spondylitis (AS) and 
domain responses in a standard index of health utility; and secondly, to implement 
the above mapping in an optimised algorithm to estimate utility. METHODS: Multi-
nomial logistic regression was used to estimate response probabilities to each domain 
of the EQ5D from the Bath Ankylosing Spondylitis Metrology Index (BASMI) among 
patients enrolled into an RCT studying the use of either etanercept infusion vs. oral 
sulphasalazine (ASCEND). Other covariates tested were gender, age, co-morbidity, AS 
duration, DMARD history, and concurrent medications. Predicted EQ5Dindex was 
estimated by Monte Carlo bootstrap simulation. The predictive ability of the response 
mapping was assessed by comparing estimated and directly measured utility derived 
from the UK tariff. RESULTS: Evaluable data were available for 566 predominantly 
white (87%) patients, 74% of whom male, with a mean baseline age of 41 years (sd 
12) and median AS duration 4 years (IQR 1 to 11). Average BASMIlinear was 4.1 (sd 
1.8) whilst median observed EQ5D utility was 0.587 (IQR 0.193 to 0.691). The linear 
deﬁnition of the BASMI was optimal in an algorithm that also adjusted for gender, 
AS duration, number of co-morbid body systems, number of historic DMARDs, 
number of current non-DMARD drugs, and current NSAID use. The mean utility 
predicted by the optimized algorithm was 0.552 (sd 0.101) and 0.559 (sd 0.295) by 
estimation directly from EQ5D responses (p = 0.238). The mean squared error 
between the actual and predicted utilities was 0.076 (sd 0.111). Adjusted utility was 
deﬁned by −0.044*BASMIlinear+0.715, with an R2 of 0.62. CONCLUSIONS: In this 
study, response mapping of AS disease activity to the EQ5Dindex produced reliable 
estimates of preference-based health-related utility. Future analysis will compare the 
relative ability of patient-reported, AS-speciﬁc, functional assessment measures in 
predicting health-related utility.
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A BAYESIAN ANALYSIS OF BISPHOSPHONATE EFFICACY FOR THE 
TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Malone DC1, Hansen GL2, Sorensen L2
1University of Arizona, Tucson, AZ, USA, 2University of Copenhagen, Copenhagen, 
Denmark
OBJECTIVES: The aim of this study was to evaluate the effectiveness of ﬁve bisphos-
phonates approved for the treatment of postmenopausal osteoporosis. METHODS: 
Randomized placebo controlled studies describing the occurrence of clinical vertebral 
(CVF), morphometric vertebral (MVF) and nonvertebral fractures (NVF) were identi-
ﬁed by searching the Cochrane Database, International Pharmaceutical Abstracts and 
Ovid Medline. Studies were eligible if patients had suffered a fracture at entry or had 
a bone mineral density at least 2 SD below the mean value for young adult females. 
WinBUGS was used to conduct the analysis, which permitted combining direct and 
indirect evidence to rank order the treatments. RESULTS: A total of 39 studies were 
identiﬁed. All ﬁve bisphosphonates were found to reduce the relative risk of new 
fractures in women with postmenopausal osteoporosis. For CVF, all ORs for treat-
ments compared to placebo were statistically signiﬁcant, suggesting that treatment 
with any agent is better than none. Zoledronate was the most effective treatment (OR 
= 0.22, 95%CRI:0.13–0.36), followed by both alendronate (OR = 0.48, 95%CRI:0.30–
0.76) and ibandronate (OR = 0.51, 95%CRI:0.34–0.77) as these could not be dif-
ferentiated statistically (no data were available for etidronate and risedronate). For 
MVF also, all ORs for treatments compared to placebo were statistically signiﬁcant. 
Zoledronate (OR = 0.28, 95%CRI:0.22–0.35) and etidronate (OR = 0.29, 
95%CRI:0.17–0.48) were both most effective, followed by alendronate (OR = 0.52, 
95%CRI:0.42–0.64), risedronate (OR = 0.56, 95% 0.45–0.70) and ibandronate (OR 
= 0.67, 95% 0.54–0.83); The last three could not be differentiated. For NVF the ORs 
for zoledronate (OR = 0.70, 95%CRI:0.60–0.80), risedronate (OR = 0.71, 
